We’re Connecting Individuals Living with ATTR-CM to a Potential New Treatment Option Designed to Deplete Amyloids
If you’ve been diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), the DepleTTR-CM Study may provide a potential new amyloid depleter treatment option that could help improve your symptoms and overall heart health.
See if you may qualifyWe are currently enrolling adults 18 to 90 years of age who have been diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). If you are interested in taking part in this study, please continue below and complete the questionnaire to determine your eligibility. This is a depleter study, which aims to target the active removal of pre-existing amyloids and restore heart function and elasticity.
We are currently enrolling adults 18 to 90 years of age who have been diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). If you are interested in taking part in this study, please continue below and complete the questionnaire to determine your eligibility. This is a depleter study, which aims to target the active removal of pre-existing amyloids and restore heart function and elasticity.